


Scaffolds for Alternative DELivery



Nanofitin[®]-based drug in Inflammatory Bowel Disease (IBD)

- A project supported by the European Commission through the Seventh Framework Programme (FP7)
- Nanofitins, a new class of non-antibody affinity ligands extremely stable
- **Administered by oral route to prevent from systemic-related side effects**
- Generated against TNF α , a target clinically validated in inflammatory bowel disorders
- Demonstrate of a **strong preventive and curative anti-inflammatory action in mice** models of Crohn and Ulcerative Colitis

Want to learn more? Come to see us at the EU Project Forum

Wednesday, March 16, 2016 from 15:00 to 18:15 @ G102 (First Floor), Amsterdam RAI